TASK DEFINITION: Given a document, an entity and its sentiment towards the entity, verify if it is the correct sentiment towards the entity. Answer should be yes or no. Note that URLs in the text have been replaced with [Link].
PROBLEM: Verify if the sentiment of the following document towards the entity Terrell Washington is Negative . Terrell  Washington   37  was charged with attempted first-degree murder and aggravated battery with a firearm after the victim identified him as her shooter  according to court records.
On Jan. 18   Washington  came over to the victimâs apartment in the 4000 block of West Gladys Avenue about 9:15 p.m.
They were talking and smoking cigarettes  and  Washington  became âincreasingly angryâ and repeatedly told the woman to lower her voice  according to Assistant Stateâs Attorney Julia Ramirez.
The woman became frustrated and told  Washington  to leave her apartment. He pulled a handgun from his waistband and shot her in the arm and leg  prosecutors said.
 Washington  then ran from the apartment through the front door  leaving it open  Ramirez said.
The victim was taken to the hospital and was treated for gunshot wounds. She later identified  Washington  as the person who shot her.
 Washington   of the 5300 block of West Adams  was arrested Friday. He was ordered held without bail during a Sunday court hearing before Judge Mary Marubio.

SOLUTION: yes

PROBLEM: Verify if the sentiment of the following document towards the entity Trumper is Negative . Thatâs not too far of a fling  actually. One really bad move could do it  but  Trump  has insulated  himself  with people far more competent and worthy of  their  positions. To date   they âre keeping  him  from stepping over the edge.
I never thought he could do the job. Heâs made some solid moves in his first year in office  but I actually give the credit to those around him. As I said from the beginning  it was the Cabinet that would do the actual work  and much like his business dealings   Trump  would be the Ronald McDonald of politics.  He âs the face of the presidency  but the actual work is being done by somebody else.
Wolff leans to some old rumors in the book about Trumpâs campaign plans. Namely   he  never intended to be president.  He  was going to clean up by being the almost president  build up a ready-made audience  and launch a new TV network venture  TrumpTV.
Because nobody thought  he  would win  nobody prepared for the job. In fact  while  Trump  bragged openly to  his  glassy-eyed followers that  he âd finance  his  own campaign and be beholden to none (How many times did I hear a Trumper say  â He  canât be bought!â)   he  put very little of  his  own money into the campaign.  He  took donations  like every other candidate  but to this day  not a single  Trump  supporter can be convinced of that.
 He  didnât run  his  campaign like somebody that wanted to win. It was a show to  him .  He  was worthless in debates  because  he  obviously didnât understand the questions being asked of  him   but  his  base would flood online polls and declare  him  the winner  even before the debates were over (which tells me they didnât understand the questions  either  nor did they care).
 Trump  struck out at Wolff on Friday night (on Twitter  of course)  slamming  him  as a âloserâ and calling  his  book âboring and untruthful.â
Ok. Wolff  however  is thanking  Trump  for helping  him  sell books  which  in turn  is opening eyes.

SOLUTION: no

PROBLEM: Verify if the sentiment of the following document towards the entity Ablynx is Neutral . PARIS/LONDON (Reuters) - French drugmaker Sanofi has agreed to buy  Belgian biotech company Ablynx  for 3.9 billion euros ($4.8 billion)  beating Novo Nordisk and marking its second big deal this month after buying Bioverativ.
The deal is a further sign of accelerating merger and acquisition (M&A) activity in the global biotech sector and comes after  Ablynx  rejected a 2.6 billion euro offer from Denmark’s Novo Nordisk.
Sanofi said on Monday it would pay 45 euros per share in cash for Ablynx  a premium of 21 percent over its closing price on Friday - and more than double the price before Novo went public with its initial bid.
Novo Nordisk conceded defeat  saying it did not intend to make a revised offer for Ablynx  which is developing a prized experimental drug for a rare blood disorder.
Sanofi said  Ablynx  would boost long-term value for  its  shareholders  while the takeover was expected to have a neutral impact on Sanofi’s business earnings per share (EPS) in 2018 and 2019.
Sanofi is already one of  Ablynx ’s big pharma partners  after striking a deal in July 2017 to find new treatments for inflammatory diseases.
By buying the company outright it will now get access to  Ablynx ’s most promising asset  the experimental drug caplacizumab for treating the rare bleeding disorder acquired thrombotic thrombocytopenic purpura.
Sanofi will be able to use its existing infrastructure and the recently acquired platform from Bioverativ to help to commercialize caplacizumab. It will also benefit from some of the other drugs  Ablynx  is working on  such as an infant anti-viral treatment  that would not have fitted within Novo Nordisk.
Berenberg analysts said  Ablynx  was a good fit but they estimated the deal would generate no more than a 4 percent return on invested capital  assuming caplacizumab sales of around 400 million euros by 2023.
The Danish group has sat out previous rounds of M&A in the drugs sector to focus on its core diabetes business but it now needs to find new products for its struggling smaller biopharmaceutical unit  where Ablynx would have been a good fit.
Morgan Stanley and Lazard advised Sanofi on the deal while JP Morgan advised Ablynx.

SOLUTION:
no